Lewe Pharma receives $100 million B-round financing

Pharmaceutical Network January 3, January 1 news, pharmaceutical new three-board listed company "Lewei Pharmaceutical" through the Chinese medical capital WeChat public number, officially announced the completion of 100 million yuan B round of financing, led by China Medical Capital, Jifeng Capital, Gaoke Xinyi, Asian Business Capital and Jingyun PharmaceuticalsThis round of financing will be used to build small molecule innovative drug production process research and development, process optimization, pilot and large-scale production and other one-stop service platformLewei Pharmaceuticals was established on October 10, 2005, the legal representative is Chen Wenxuan, headquartered in Jiangsu, specializing in the industrialization of innovative pharmaceutical industry outsourcing services, the scope of services covering innovative medicine from the laboratory to industrialization of the process transformation, including pre-clinical to approved after the listing of process research and development, process optimization, pilot and large-scale productionOn October 26, 2016, Lewe Pharma was listed on the new three boardsAt present, Lewei Pharmaceuticals owns five wholly-owned subsidiaries of Beijing Lewei, Beijing Kangfu, Tianjin Lewei, Jiangsu BeiqingKang and Lewei, among which the subsidiary of the United States Lewei for overseas sales subsidiaries and major U.Scustomers to establish long-term cooperative relations, for local customers to provide local servicesAccording to the prospectus of Lewei Pharmaceuticals, the controlling shareholders of Lewei Pharma are Chen Wenxuan, Yang Guang and one line of environmental protection, and the actual controllers are Chen Wenxuan, Yang Guang and Chen HongqingAmong them, Chen Wenxuan graduated from Tsinghua University and New Mexico State University with a master's degreeSince 1993, Chen has served as an assistant researcher, researcher and senior researcher in the new drug development and development department of Skbiting Pharmaceuticals of the United States, DuPont Pharmaceuticals of the United States, and BoxEme Pharmaceuticals pharmaceutical company of the United StatesFrom April 2010 to October 2015, Chen Wenxuan served as Executive Director, Chairman and General Manager of Warwick Pharmaceuticals, and as Chairman, General Manager and Ceo of Warwick Pharmaceuticals from November 2015 to dateIn addition, Chen Wenxuan is the main inventor of the international patent for the international invention of 15 innovative drugs for antidepressants and metabolic diseasesYang Guang, chief scientist ofLewe Sin, graduated from Peking University and the University of California, Irvine, USA, with a Ph.Ddegree, and later engaged in postdoctoral research at The Scripps Research Institute in San Diego, USAHe has served as an Assistant Researcher and Senior Scientist at Kunlun Pharmaceutical Services Co., Ltdand Sugen, Incin BeijingChen Hongqing, chief operating officer of Lewei Pharmaceuticals, has served as assistant general manager, deputy director and general manager of Jiangyu Fertilizer Co., Ltdand Beijing Haimingyuan Science and Trade Development Co., Ltdin Jiangyu City, Jiangsu Provincethe process research and pilot of innovative drugs is an important link in the process of innovation drug research and development, in which the innovative drug intermediate is the intermediate substance in the process of raw material synthesis process, belongs to the fine chemicals of medicine, and now takes the chemical synthesisas an example, explains the position of the innovative drug intermediate in the pharmaceutical production process:innovative drug intermediate custom research and development production service is refined into custom research and development services and custom production services, the two together constitute the whole of the business of theand subsidiary companies, mainly used in the field of pharmaceutical manufacturingAmong them, custom research and development refers to the provision of pharmaceutical intermediates for innovative drugs, such as process development, quality research and safety research services, mainly provided by Beijing Lewei, customized production refers to the provision of pharmaceutical intermediates for innovative drugs non-GMP pilot research and development and customized production services, including the technology development phase of non-GMP pilot research and development production services to the commercialization stage of industrial production services, mainly by Lewei Pharmaceuticals to provide servicesBoth are high value-added services that reduce the cost of pharmaceuticalresearch and development and production, while enabling pharmaceutical companies to effectively control research and development risks and improve research and development efficiency, optimize the supply chain, and bring new products to market fasterclassified by life cycle, drugs can be divided into innovative drugs and generic drugs, Lewe pharmaceuticals mainly serve innovative drugs, especially in which the new molecular entities of the customized research and development and production servicesAt present, Lewe Pharmaceuticals serves more than 300 project orders, involving disease treatment areas covering anti-cancer, anti-tumor, anti-diabetes, etc, has been with Sage, Gilead, BMS and other internationally renowned customers to establish a long-term strategic partnershipPharmaceutical CMO/CDMO industry is a highly marketable and fully competitive industryAccording to BusinessInsight, as of the end of 2011, there were only five CMO/CDMO companies in the world with more than $500 million in revenue from pharmaceutical outsourcing servicesFrom a worldwide perspective, pharmaceutical CMO/CDMO enterprises mainly serve pharmaceutical companies and biotechnology companies in developed regions such as Europe, the United States and Japan At present, the world's CMO/CDMO enterprises are mainly concentrated in Europe and the United States and Asia, of which the Asian market CMO/CDMO enterprises are mainly concentrated in China and India China has become an increasingly preferred strategic outsourcing destination for multinational pharmaceutical companies by virtue of its competitive advantage sonby in , infrastructure and cost structure China's pharmaceutical CMO market has maintained a growth rate of more than 10% in recent years, according to Informa's forecast, the average growth rate of China's pharmaceutical CMO market in 2012-2017 is 17.4%, the market size will reach 5 billion U.S dollars in 2017 In terms of market structure, the average growth rate of clinical production is 9.5%, while the average growth rate of commercial production will reach 18.7% and as early as December 27, 2017, Lewe Pharmaceuticals issued a stock issuance plan, raising total assets of not more than 100 million yuan, mainly used for the construction of cdMO base base projects (phase 1), including land acquisition and related taxes and fees, construction costs, equipment and equipment costs, installation works, design survey supervision and related supporting costs the stock issue plan said that the construction of cdMO (new drug custom research and development and production services) base in line with the standards, will further expand the overall research and development capacity and production capacity, broaden the Lewe pharmaceutical industry chain, meet customer's customized needs, maintain and further strengthen the Technology Leading Position and research and development advantages of the Lewe Group, effectively enhance the core competitiveness of enterprises, and promote the upgrading of the industrial chain.